Ruifang Li-Gao
Leiden University Medical Center
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Ruifang Li-Gao.
Journal of Medical Genetics | 2016
Elisabeth M. van Leeuwen; Aniko Sabo; Joshua C. Bis; Jennifer E. Huffman; Ani Manichaikul; Albert V. Smith; Mary F. Feitosa; Serkalem Demissie; Peter K. Joshi; Qing Duan; Jonathan Marten; Jan B. van Klinken; Ida Surakka; Ilja M. Nolte; Weihua Zhang; Hamdi Mbarek; Ruifang Li-Gao; Stella Trompet; Niek Verweij; Evangelos Evangelou; Leo-Pekka Lyytikäinen; Bamidele O. Tayo; Joris Deelen; Peter J. van der Most; Sander W. van der Laan; Dan E. Arking; Alanna C. Morrison; Abbas Dehghan; Oscar H. Franco; Albert Hofman
Background So far, more than 170 loci have been associated with circulating lipid levels through genome-wide association studies (GWAS). These associations are largely driven by common variants, their function is often not known, and many are likely to be markers for the causal variants. In this study we aimed to identify more new rare and low-frequency functional variants associated with circulating lipid levels. Methods We used the 1000 Genomes Project as a reference panel for the imputations of GWAS data from ∼60 000 individuals in the discovery stage and ∼90 000 samples in the replication stage. Results Our study resulted in the identification of five new associations with circulating lipid levels at four loci. All four loci are within genes that can be linked biologically to lipid metabolism. One of the variants, rs116843064, is a damaging missense variant within the ANGPTL4 gene. Conclusions This study illustrates that GWAS with high-scale imputation may still help us unravel the biological mechanism behind circulating lipid levels.
Circulation-cardiovascular Genetics | 2016
Pradeep Natarajan; Joshua C. Bis; Lawrence F. Bielak; Amanda J. Cox; Marcus Dörr; Mary F. Feitosa; Nora Franceschini; Xiuqing Guo; Shih Jen Hwang; Aaron Isaacs; Min A. Jhun; Maryam Kavousi; Ruifang Li-Gao; Leo-Pekka Lyytikäinen; Riccardo E. Marioni; Ulf Schminke; Nathan O. Stitziel; Hayato Tada; Jessica van Setten; Albert V. Smith; Dina Vojinovic; Lisa R. Yanek; Jie Yao; Laura M. Yerges-Armstrong; Najaf Amin; Usman Baber; Ingrid B. Borecki; J. Jeffrey Carr; Yii-Der Ida Chen; L. Adrienne Cupples
Background—The burden of subclinical atherosclerosis in asymptomatic individuals is heritable and associated with elevated risk of developing clinical coronary heart disease. We sought to identify genetic variants in protein-coding regions associated with subclinical atherosclerosis and the risk of subsequent coronary heart disease. Methods and Results—We studied a total of 25 109 European ancestry and African ancestry participants with coronary artery calcification (CAC) measured by cardiac computed tomography and 52 869 participants with common carotid intima–media thickness measured by ultrasonography within the CHARGE Consortium (Cohorts for Heart and Aging Research in Genomic Epidemiology). Participants were genotyped for 247 870 DNA sequence variants (231 539 in exons) across the genome. A meta-analysis of exome-wide association studies was performed across cohorts for CAC and carotid intima–media thickness. APOB p.Arg3527Gln was associated with 4-fold excess CAC (P=3×10−10). The APOE &egr;2 allele (p.Arg176Cys) was associated with both 22.3% reduced CAC (P=1×10−12) and 1.4% reduced carotid intima–media thickness (P=4×10−14) in carriers compared with noncarriers. In secondary analyses conditioning on low-density lipoprotein cholesterol concentration, the &egr;2 protective association with CAC, although attenuated, remained strongly significant. Additionally, the presence of &egr;2 was associated with reduced risk for coronary heart disease (odds ratio 0.77; P=1×10−11). Conclusions—Exome-wide association meta-analysis demonstrates that protein-coding variants in APOB and APOE associate with subclinical atherosclerosis. APOE &egr;2 represents the first significant association for multiple subclinical atherosclerosis traits across multiple ethnicities, as well as clinical coronary heart disease.
Journal of Medical Genetics | 2017
Raymond Noordam; Colleen M. Sitlani; Christy L. Avery; James D. Stewart; Stephanie M. Gogarten; Kerri L. Wiggins; Stella Trompet; Helen R. Warren; Fangui Sun; Daniel S. Evans; Xiaohui Li; Jin Li; Albert V. Smith; Joshua C. Bis; Jennifer A. Brody; Evan L. Busch; Mark J. Caulfield; Yii-Der I. Chen; Steven R. Cummings; L. Adrienne Cupples; Qing Duan; Oscar H. Franco; Raúl Méndez-Giráldez; Tamara B. Harris; Susan R. Heckbert; Diana van Heemst; Albert Hofman; James S. Floyd; Jan A. Kors; Lenore J. Launer
Background Increased heart rate and a prolonged QT interval are important risk factors for cardiovascular morbidity and mortality, and can be influenced by the use of various medications, including tricyclic/tetracyclic antidepressants (TCAs). We aim to identify genetic loci that modify the association between TCA use and RR and QT intervals. Methods and results We conducted race/ethnic-specific genome-wide interaction analyses (with HapMap phase II imputed reference panel imputation) of TCAs and resting RR and QT intervals in cohorts of European (n=45 706; n=1417 TCA users), African (n=10 235; n=296 TCA users) and Hispanic/Latino (n=13 808; n=147 TCA users) ancestry, adjusted for clinical covariates. Among the populations of European ancestry, two genome-wide significant loci were identified for RR interval: rs6737205 in BRE (β=56.3, pinteraction=3.9e−9) and rs9830388 in UBE2E2 (β=25.2, pinteraction=1.7e−8). In Hispanic/Latino cohorts, rs2291477 in TGFBR3 significantly modified the association between TCAs and QT intervals (β=9.3, pinteraction=2.55e−8). In the meta-analyses of the other ethnicities, these loci either were excluded from the meta-analyses (as part of quality control), or their effects did not reach the level of nominal statistical significance (pinteraction>0.05). No new variants were identified in these ethnicities. No additional loci were identified after inverse-variance-weighted meta-analysis of the three ancestries. Conclusions Among Europeans, TCA interactions with variants in BRE and UBE2E2 were identified in relation to RR intervals. Among Hispanic/Latinos, variants in TGFBR3 modified the relation between TCAs and QT intervals. Future studies are required to confirm our results.
American Journal of Human Genetics | 2018
Carolina Medina-Gomez; John P. Kemp; Katerina Trajanoska; Jian'an Luan; Alessandra Chesi; Tarunveer S. Ahluwalia; Dennis O. Mook-Kanamori; Annelies C. Ham; Fernando Pires Hartwig; Daniel S. Evans; Raimo Joro; Ivana Nedeljkovic; Hou-Feng Zheng; Kun Zhu; Mustafa Atalay; Ching-Ti Liu; Maria Nethander; Linda Broer; Gudmar Porleifsson; Benjamin H. Mullin; Samuel K. Handelman; Michael A. Nalls; Leon Eyrich Jessen; Denise H. M. Heppe; J. Brent Richards; Carol A. Wang; Bo L. Chawes; Katharina E. Schraut; Najaf Amin; Nicholas J. Wareham
Bone mineral density (BMD) assessed by DXA is used to evaluate bone health. In children, total body (TB) measurements are commonly used; in older individuals, BMD at the lumbar spine (LS) and femoral neck (FN) is used to diagnose osteoporosis. To date, genetic variants in more than 60 loci have been identified as associated with BMD. To investigate the genetic determinants of TB-BMD variation along the life course and test for age-specific effects, we performed a meta-analysis of 30 genome-wide association studies (GWASs) of TB-BMD including 66,628 individuals overall and divided across five age strata, each spanning 15 years. We identified variants associated with TB-BMD at 80 loci, of which 36 have not been previously identified; overall, they explain approximately 10% of the TB-BMD variance when combining all age groups and influence the risk of fracture. Pathway and enrichment analysis of the association signals showed clustering within gene sets implicated in the regulation of cell growth and SMAD proteins, overexpressed in the musculoskeletal system, and enriched in enhancer and promoter regions. These findings reveal TB-BMD as a relevant trait for genetic studies of osteoporosis, enabling the identification of variants and pathways influencing different bone compartments. Only variants in ESR1 and close proximity to RANKL showed a clear effect dependency on age. This most likely indicates that the majority of genetic variants identified influence BMD early in life and that their effect can be captured throughout the life course.
Pharmacogenomics Journal | 2018
James S. Floyd; Colleen M. Sitlani; Christy L. Avery; Raymond Noordam; Xiaohui Li; Albert V. Smith; Stephanie M. Gogarten; Jun Li; Linda Broer; Daniel S. Evans; Stella Trompet; Jennifer A. Brody; James D. Stewart; John D. Eicher; A A Seyerle; Jeffrey Roach; Leslie A. Lange; Henry J. Lin; Jan A. Kors; T. B. Harris; Ruifang Li-Gao; Naveed Sattar; Steven R. Cummings; Kerri L. Wiggins; Melanie D. Napier; Til Stürmer; J. C. Bis; Kathleen F. Kerr; A.G. Uitterlinden; Kent D. Taylor
Sulfonylureas, a commonly used class of medication used to treat type 2 diabetes, have been associated with an increased risk of cardiovascular disease. Their effects on QT interval duration and related electrocardiographic phenotypes are potential mechanisms for this adverse effect. In 11 ethnically diverse cohorts that included 71 857 European, African-American and Hispanic/Latino ancestry individuals with repeated measures of medication use and electrocardiogram (ECG) measurements, we conducted a pharmacogenomic genome-wide association study of sulfonylurea use and three ECG phenotypes: QT, JT and QRS intervals. In ancestry-specific meta-analyses, eight novel pharmacogenomic loci met the threshold for genome-wide significance (P<5 × 10−8), and a pharmacokinetic variant in CYP2C9 (rs1057910) that has been associated with sulfonylurea-related treatment effects and other adverse drug reactions in previous studies was replicated. Additional research is needed to replicate the novel findings and to understand their biological basis.
Circulation: Genomic and Precision Medicine | 2018
Lisanne L. Blauw; Ruifang Li-Gao; Raymond Noordam; Renée de Mutsert; S. Trompet; Jimmy F.P. Berbée; Yanan Wang; Jan B. van Klinken; Tim Christen; Diana van Heemst; Dennis O. Mook-Kanamori; Frits R. Rosendaal; J. Wouter Jukema; Patrick C. N. Rensen; Ko Willems van Dijk
Background: We aimed to identify independent genetic determinants of circulating CETP (cholesteryl ester transfer protein) to assess causal effects of variation in CETP concentration on circulating lipid concentrations and cardiovascular disease risk. Methods: A genome-wide association discovery and replication study on serum CETP concentration were embedded in the NEO study (Netherlands Epidemiology of Obesity). Based on the independent identified variants, Mendelian randomization was conducted on serum lipids (NEO study) and coronary artery disease (CAD; CARDIoGRAMplusC4D consortium). RESULTS: In the discovery analysis (n=4248), we identified 3 independent variants (P<5×10−8) that determine CETP concentration. These single-nucleotide polymorphisms were mapped to CETP and replicated in a separate subpopulation (n=1458). Per-allele increase (SE) in serum CETP was 0.32 (0.02) µg/mL for rs247616-C, 0.35 (0.02) µg/mL for rs12720922-A, and 0.12 (0.02) µg/mL for rs1968905-G. Combined, these 3 variants explained 16.4% of the total variation in CETP concentration. One microgram per milliliter increase in genetically determined CETP concentration strongly decreased high-density lipoprotein cholesterol (−0.23 mmol/L; 95% confidence interval, −0.26 to −0.20), moderately increased low-density lipoprotein cholesterol (0.08 mmol/L; 95% confidence interval, 0.00–0.16), and was associated with an odds ratio of 1.08 (95% confidence interval, 0.94–1.23) for CAD risk. Conclusions: This is the first genome-wide association study identifying independent variants that largely determine CETP concentration. Although high-density lipoprotein cholesterol is not a causal risk factor for CAD, it has been unequivocally demonstrated that low-density lipoprotein cholesterol lowering is proportionally associated with a lower CAD risk. Therefore, the results of our study are fully consistent with the notion that CETP concentration is causally associated with CAD through low-density lipoprotein cholesterol.
Research and Practice in Thrombosis and Haemostasis | 2018
Inge M. Rietveld; Mettine H. A. Bos; Willem M. Lijfering; Ruifang Li-Gao; Frits R. Rosendaal; P. H. Reitsma; Suzanne C. Cannegieter
Essentials No clear association between FV concentration and venous thrombosis (VT) has been described yet. This association was studied in a large case‐control study on VT (MEGA‐study). Both high and low FV levels were associated with VT risk. Association with high FV levels was dependent on FVIII levels, that with low FV levels was not.
Physiological Genomics | 2018
Ruifang Li-Gao; Salma M. Wakil; Brian F. Meyer; Nduna Dzimiri; Dennis O. Mook-Kanamori
Over 120 Type 2 diabetes (T2D) loci have been identified from genome-wide association studies (GWAS), mainly from Caucasian populations. Very limited knowledge is available on the Saudi Arabian population. In this study, 122 previously reported T2D-related variants from 84 loci were examined in a Saudi Arabian cohort of 1,578 individuals (659 T2D cases and 919 controls). Eleven single nucleotide polymorphisms (SNPs) corresponding to nine independent loci had a P value <0.05. If a more stringent Bonferroni threshold of P = 4.1 × 10−4 ( = 0.05/122) were applied, none of the SNPs would have reached the significance level. Nine of the SNPs with a P value <0.05 showed similar odds ratios as previously described, but rs11605924 (CRY2) and rs9470794 (ZFAND3) were in the opposite direction. This study demonstrates the importance of large-scale GWAS in the Saudi Arabian population to identify ethnicity-specific disease-associated variants.
Physiological Genomics | 2018
Ruifang Li-Gao; Renée de Mutsert; Frits R. Rosendaal; Ko Willems van Dijk; Dennis O. Mook-Kanamori
In 2015, a genome-wide association study described 59 independent signals that showed strong associations with 85 fasting metabolite concentrations as measured by the Biocrates AbsoluteIDQ p150 kit. However, the human body resides in a nonfasting state for the greater part of the day, and the genetic basis of postprandial metabolite concentrations remains largely unknown. We systematically examined these previously identified genetic associations in postprandial metabolite concentrations after a mixed meal. Of these 85 metabolites, 23 were identified with significant changes after the meal, for which 38 gene-metabolite associations were analyzed. Of these 38 associations, 31 gene-metabolite associations were replicated with postprandial metabolite concentrations. These data indicate that the genetics of fasting and postprandial metabolite levels are significantly overlapping.
Pharmacogenomics Journal | 2017
Amanda A. Seyerle; Colleen M. Sitlani; Raymond Noordam; Stephanie M. Gogarten; J. Li; Xin Li; Daniel S. Evans; Fangui Sun; Maarit A. Laaksonen; Aaron Isaacs; Kati Kristiansson; Heather M. Highland; James D. Stewart; T. B. Harris; S. Trompet; J. C. Bis; Gina M. Peloso; Jennifer A. Brody; Linda Broer; Evan L. Busch; Qing Duan; A. M. Stilp; Christoper J. O'Donnell; Peter W. Macfarlane; James S. Floyd; Jan A. Kors; Henry J. Lin; Ruifang Li-Gao; Tamar Sofer; Raúl Méndez-Giráldez
Thiazide diuretics, commonly used antihypertensives, may cause QT interval (QT) prolongation, a risk factor for highly fatal and difficult to predict ventricular arrhythmias. We examined whether common single-nucleotide polymorphisms (SNPs) modified the association between thiazide use and QT or its component parts (QRS interval, JT interval) by performing ancestry-specific, trans-ethnic and cross-phenotype genome-wide analyses of European (66%), African American (15%) and Hispanic (19%) populations (N=78 199), leveraging longitudinal data, incorporating corrected standard errors to account for underestimation of interaction estimate variances and evaluating evidence for pathway enrichment. Although no loci achieved genome-wide significance (P<5 × 10−8), we found suggestive evidence (P<5 × 10−6) for SNPs modifying the thiazide-QT association at 22 loci, including ion transport loci (for example, NELL1, KCNQ3). The biologic plausibility of our suggestive results and simulations demonstrating modest power to detect interaction effects at genome-wide significant levels indicate that larger studies and innovative statistical methods are warranted in future efforts evaluating thiazide–SNP interactions.